Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients

Ibrutinib is a selective oral Burton tyrosine kinase (BTK) inhibitor that interfering with the downstream pathways of B-cell receptor signaling inhibits proliferation and induces apoptosis in many ...